{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:21:05Z","timestamp":1759191665124,"version":"3.44.0"},"reference-count":28,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bras Pneumol."],"abstract":"<jats:p>Objective: Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute pulmonary embolism, being characterized by persistent obstruction of pulmonary vessels and leading to increased pulmonary vascular resistance and right ventricular failure. Although pulmonary endarterectomy is the preferred treatment, medical therapies may offer clinical benefits in specific settings. We sought to evaluate the clinical and hemodynamic response of CTEPH patients treated with sildenafil and ambrisentan upfront combination therapy. Methods: This was a retrospective cohort study including patients with operable and inoperable CTEPH. The patients were followed from 2019 to 2022 and were treated with sildenafil and ambrisentan as first-line therapy. Results: Functional and hemodynamic data were analyzed at baseline and after a minimum of six months of therapy. Following treatment, there was a notable improvement in functional class, natriuretic peptide levels, and invasive hemodynamics. Conclusions: The combined use of sildenafil and ambrisentan appears to be associated with clinical, functional, and hemodynamic improvement in patients with CTEPH.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20250056","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T18:57:37Z","timestamp":1759172257000},"page":"e20250056","source":"Crossref","is-referenced-by-count":0,"title":["Upfront combination therapy with sildenafil and ambrisentan in patients with chronic thromboembolic pulmonary hypertension"],"prefix":"10.36416","author":[{"given":"William","family":"Salibe-Filho1","sequence":"first","affiliation":[{"name":"1. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Leonidas Alves-Junior1","sequence":"additional","affiliation":[{"name":"1. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yally","family":"Priscila Pess\u00f4a Nascimento1","sequence":"additional","affiliation":[{"name":"1. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiza","family":"Sarmento Tatagiba1","sequence":"additional","affiliation":[{"name":"1. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caio","family":"Julio Cesar Fernandes1","sequence":"additional","affiliation":[{"name":"1. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Viana Poyares Jardim1","sequence":"additional","affiliation":[{"name":"1. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Terra-Filho1","sequence":"additional","affiliation":[{"name":"1. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogerio","family":"Souza1","sequence":"additional","affiliation":[{"name":"1. Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7\u00e3o, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22288","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.           Marti D, Gomez V, Escobar C, Wagner C, Zamarro C, Sanchez D, et al. Incidence of symptomatic and asymptomatic chronic thromboembolic pulmonary hypertension [Article in Spanish]. Arch Bronconeumol. 2010;46(12):628-33. https:\/\/doi.org\/10.1016\/S1579-2129(10)70137-3","DOI":"10.1016\/s1579-2129(10)70137-3"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.           Fernandes C, Ota-Arakaki JS, Campos F, Correa RA, Gazzana MB, Jardim CVP, et al. Brazilian Thoracic Society recommendations for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension. J Bras Pneumol. 2022;46(4):e20200204. https:\/\/doi.org\/10.36416\/1806-3756\/e20200204","DOI":"10.36416\/1806-3756\/e20200204"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.           Lang IM, Dorfmuller P, Vonk Noordegraaf A. The Pathobiology of Chronic Thromboembolic Pulmonary Hypertension. Ann Am Thorac Soc. 2016;13 Suppl 3:S215-21. https:\/\/doi.org\/10.1513\/AnnalsATS.201509-620AS","DOI":"10.1513\/annalsats.201509-620as"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.           Sharma S, Hofbauer TM, Ondracek AS, Chausheva S, Alimohammadi A, Artner T, et al. Neutrophil extracellular traps promote fibrous vascular occlusions in chronic thrombosis. Blood. 2021;137(8):1104-16. https:\/\/doi.org\/10.1182\/blood.2020005861","DOI":"10.1182\/blood.2020005861"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.           Dorfmuller P, Gunther S, Ghigna MR, Thomas de Montpreville V, Boulate D, Paul JF, et al. Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. Eur Respir J. 2014;44(5):1275-88. https:\/\/doi.org\/10.1183\/09031936.00169113","DOI":"10.1183\/09031936.00169113"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.           Fassel H, Chen H, Ruisi M, Kumar N, DeSancho M, Hajjar KA. Reduced expression of annexin A2 is associated with impaired cell surface fibrinolysis and venous thromboembolism. Blood. 2021;137(16):2221-30. https:\/\/doi.org\/10.1182\/blood.2020008123","DOI":"10.1182\/blood.2020008123"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.           Salibe-Filho W, Araujo TLS, G Melo E, B C T Coimbra L, Lapa MS, Acencio MMP, et al. Shear stress-exposed pulmonary artery endothelial cells fail to upregulate HSP70 in chronic thromboembolic pulmonary hypertension. PLoS One. 2020;15(12):e0242960. https:\/\/doi.org\/10.1371\/journal.pone.0242960","DOI":"10.1371\/journal.pone.0242960"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.           Jais X, Brenot P, Bouvaist H, Jevnikar M, Canuet M, Chabanne C, et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respir Med. 2022;10(10):961-71. https:\/\/doi.org\/10.1016\/S2213-2600(22)00214-4","DOI":"10.1016\/s2213-2600(22)00214-4"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.           Kawakami T, Matsubara H, Shinke T, Abe K, Kohsaka S, Hosokawa K, et al. Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): an open-label, randomised controlled trial. Lancet Respir Med. 2022;10(10):949-60. https:\/\/doi.org\/10.1016\/S2213-2600(22)00171-0","DOI":"10.1016\/s2213-2600(22)00171-0"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10.        Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53(1):1801915. https:\/\/doi.org\/10.1183\/13993003.01915-2018","DOI":"10.1183\/13993003.01915-2018"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.        Jais X, D\u2019Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52(25):2127-34. https:\/\/doi.org\/10.1016\/j.jacc.2008.08.059","DOI":"10.1016\/j.jacc.2008.08.059"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.        Ghofrani HA, D\u2019Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319-29. https:\/\/doi.org\/10.1056\/NEJMoa1209657","DOI":"10.1056\/nejmoa1209657"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.        Ghofrani HA, Simonneau G, D\u2019Armini AM, Fedullo P, Howard LS, Jais X, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 2024;12(4):e21-e30. https:\/\/doi.org\/10.1016\/S2213-2600(24)00029-8","DOI":"10.1016\/s2213-2600(24)00029-8"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.        Escribano-Subias P, Bendjenana H, Curtis PS, Lang I, Vonk Noordegraaf A. Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Pulm Circ. 2019;9(2):2045894019846433. https:\/\/doi.org\/10.1177\/2045894019846433","DOI":"10.1177\/2045894019846433"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.        Chin KM, Gaine SP, Gerges C, Jing ZC, Mathai SC, Tamura Y, et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. 2024;64(4)2401325. https:\/\/doi.org\/10.1183\/13993003.01325-2024","DOI":"10.1183\/13993003.01325-2024"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.        Fernandes CJ, Calderaro D, Assad APL, Salibe-Filho W, Kato-Morinaga LT, Hoette S, et al. Update on the Treatment of Pulmonary Arterial Hypertension. Arq Bras Cardiol. 2021;117(4):750-64. https:\/\/doi.org\/10.36660\/abc.20200702","DOI":"10.36660\/abc.20200702"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17.        Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(9):834-44. https:\/\/doi.org\/10.1056\/NEJMoa1413687","DOI":"10.1056\/nejmoa1413687"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.        van Thor MCJ, Snijder RJ, Kelder JC, Mager JJ, Post MC. Does combination therapy work in chronic thromboembolic pulmonary hypertension? Int J Cardiol Heart Vasc. 2020;29:100544. https:\/\/doi.org\/10.1016\/j.ijcha.2020.100544","DOI":"10.1016\/j.ijcha.2020.100544"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19.        Frost A, Badesch D, Gibbs JSR, Gopalan D, Khanna D, Manes A, et al. Diagnosis of pulmonary hypertension. Eur Respir J. 2019;53(1):1801904. https:\/\/doi.org\/10.1183\/13993003.01904-2018","DOI":"10.1183\/13993003.01904-2018"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.        Pepke-Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011;124(18):1973-81. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.015008","DOI":"10.1161\/CIRCULATIONAHA.110.015008"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21.        Cannon JE, Su L, Kiely DG, Page K, Toshner M, Swietlik E, et al. Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort. Circulation. 2016;133(18):1761-71. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.019470","DOI":"10.1161\/circulationaha.116.024416"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22.        Delcroix M, Pepke-Zaba J, D\u2019Armini AM, Fadel E, Guth S, Hoole SP, et al. Worldwide CTEPH Registry: Long-Term Outcomes With Pulmonary Endarterectomy, Balloon Pulmonary Angioplasty, and Medical Therapy. Circulation. 2024;150(17):1354-65. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.068610","DOI":"10.1161\/circulationaha.124.068610"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23.        Pepke-Zaba J, Ghofrani HA, Hoeper MM. Medical management of chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017;26(143):160107. https:\/\/doi.org\/10.1183\/16000617.0107-2016","DOI":"10.1183\/16000617.0107-2016"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24.        Kim NH, D\u2019Armini AM, Delcroix M, Jais X, Jevnikar M, Madani MM, et al. Chronic thromboembolic pulmonary disease. Eur Respir J. 2024;64(4):2401294. https:\/\/doi.org\/10.1183\/13993003.01294-2024","DOI":"10.1183\/13993003.01294-2024"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25.        Castro MA, Piloto B, Dos Santos Fernandes CJC, Jardim C, Filho WS, Oleas FG, et al. Use of medical therapies before pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension patients with severe hemodynamic impairment. PLoS One. 2020;15(5):e0233063. https:\/\/doi.org\/10.1371\/journal.pone.0233063","DOI":"10.1371\/journal.pone.0233063"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26.        Kim NH, Channick R, Delcroix M, Madani M, Pepke-Zaba J, Borissoff JI, et al. Efficacy and safety of selexipag in patients with inoperable or persistent\/recurrent CTEPH (SELECT randomised trial). Eur Respir J. 2024;64(4):2400193. https:\/\/doi.org\/10.1183\/13993003.00193-2024","DOI":"10.1183\/13993003.00193-2024"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.        Kim NH, D\u2019Armini AM, Howard LS, Jenkins DP, Jing ZC, Mayer E, et al. Long-Term Safety and Efficacy of Macitentan in Inoperable Chronic Thromboembolic Pulmonary Hypertension: Results from MERIT and its Open-Label Extension. Pulm Ther. 2025;11(1):101-116. https:\/\/doi.org\/10.1007\/s41030-024-00276-w","DOI":"10.1007\/s41030-024-00276-w"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28.        Chin KM, Sitbon O, Doelberg M, Feldman J, Gibbs JSR, Grunig E, et al. Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2021;78(14):1393-403. https:\/\/doi.org\/10.1016\/j.jacc.2021.07.057","DOI":"10.1016\/j.jacc.2021.07.057"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T18:57:39Z","timestamp":1759172259000},"score":1,"resource":{"primary":{"URL":"https:\/\/jornaldepneumologia.com.br\/details\/4158\/en-US"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,13]]},"references-count":28,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20250056","relation":{},"ISSN":["1806-3756"],"issn-type":[{"value":"1806-3756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,13]]}}}